Dexcom posted first-quarter 2026 results ahead of Wall Street expectations, with revenue up 15% to $1.19 billion and adjusted EPS of $0.56. The company raised its operating and EBITDA margin outlooks ...
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results